



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/894,924	06/28/2001	Avi J. Ashkenazi	P1134R2C1	1667
9157	7590	03/03/2004	EXAMINER	
GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080			KAUFMAN, CLAIRE M	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 03/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.

EXAMINER

ART UNIT PAPER

0204

DATE MAILED:

Commissioner for Patents

Examiner's Amendment is attached.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed.

Authorization for this examiner's amendment was given in a telephone interview with Jeffrey Kushan on February 26, 2004. To further prosecution of the instant application, Applicants request an Examiner's amendment to cancel claims 68, 73, and 78. It is Applicants' intention to pursue these claims in another application.

The application has been amended as follows: Claims 68, 73 and 77 are canceled as indicated in the complete listing of claims below.

Complete Listing of the Claims

1-13. (canceled)

14. (previously amended) An isolated antibody which binds to a DcR3 polypeptide, wherein said DcR3 polypeptide (a) comprises amino acids 1 to 300 of Fig. 1 (SEQ ID NO:1) or (b) comprises amino acids 1 to X, wherein X is any one of amino acids 215 to 300 of Fig. 1 (SEQ ID NO:1).

15-66. (canceled)

67. (previously presented) The antibody of claim 14 wherein said antibody is a monoclonal antibody.

68. (canceled)

69. (previously presented) The antibody of claim 67 wherein said antibody is a chimeric antibody.

70. (previously presented) The antibody of claim 67 wherein said antibody is a human antibody.

71. (previously amended) The antibody of claim 14 wherein said antibody binds to a DcR3 polypeptide consisting of amino acids 1 to 300 of Fig. 1 (SEQ ID NO:1).

72. (previously presented) The antibody of claim 71 wherein said antibody is a monoclonal antibody.

73. (canceled)

74. (previously presented) The antibody of claim 72 wherein said antibody is a chimeric antibody.

75. (previously presented) The antibody of claim 72 wherein said antibody is a human antibody.

76. (previously amended) The antibody of claim 14 wherein said antibody binds to a DcR3 polypeptide consisting of amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1).

77. (previously presented) The antibody of claim 76 wherein said antibody is a monoclonal antibody.

78. (canceled)

79. (previously presented) The antibody of claim 77 wherein said antibody is a chimeric antibody.

80. (previously presented) The antibody of claim 77 wherein said antibody is a human antibody.

81. (previously amended) An isolated monoclonal antibody which binds to a DcR3 polypeptide consisting of amino acids 1 to 300 of Fig. 1 (SEQ ID NO:1) or consisting of amino acids 1 to 215 of Fig. 1 (SEQ ID NO:1).

82. (previously presented) The antibody of claim 80 wherein said antibody is a chimeric antibody.

83. (previously presented) The antibody of claim 80 wherein said antibody is a human antibody.

84. (previously presented) The antibody of claim 80 wherein said antibody is expressed in a recombinant host cell selected from the group consisting of a CHO cell, yeast cell and *E. coli*.

85. (previously presented) The antibody of claim 80 wherein said antibody is linked to a detectable moiety selected from the group consisting of one or more radioisotopes, fluorescent compounds, chemiluminescent compounds, and enzymes.

Art Unit: 1646

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571)272-0873. Dr. Kaufman can generally be reached Monday, Tuesday and Thursday from 8:30AM to 2:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached at (571)272-0871.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.


Official papers filed by fax should be directed to (703) 872-9306. NOTE: If applicant does submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Claire M. Kaufman, Ph.D.



Patent Examiner, Art Unit 1646

February 26, 2004



LORRAINE SPECTOR
PRIMARY EXAMINER